Anita R.
- Country
- The Netherlands
- Department
- Hematology
Research Overview
- Phase 1/2 Study of Subcutaneous Blinatumomab in Adults and Adolescents with Relapsed/Refractory or MRD+ B-cell Precursor Acute Lymphoblastic Leukemia
- Phase 2/3 Randomized Open‑Label Study of MK‑1045 Versus Blinatumomab in Relapsed/Refractory CD19‑Positive B‑Cell Acute Lymphoblastic Leukemia
- Efficacy and Safety Evaluation of Mitapivat in Patients with Sickle Cell Disease: A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Multicenter Study
Data & Insights
Has run more than one trial at 55 of 107 partner sites.
Specializations
Hematologic Malignancies
Acute myeloid leukemia, myelodysplastic syndrome, myelofibrosis, multiple myeloma, and lymphoid neoplasms form a major part of the clinical research portfolio, with activity spanning both relapsed and newly diagnosed disease settings. The therapeutic focus also includes Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and other advanced blood and lymphatic diseases.
- Acute myeloid leukemia
- Multiple myeloma
- Lymphoma
- Myelodysplastic syndrome
- Myelofibrosis
Research interests extend to cell therapy, transplant-related hematology, and treatment strategies for refractory or high-risk hematologic disease.
Solid Tumors and Precision Oncology
The investigator is actively involved in studies of non-small cell lung cancer, small cell lung cancer, urothelial carcinoma, breast cancer, prostate cancer, ovarian cancer, and pancreatic cancer. Additional areas include cholangiocarcinoma, gastric cancer, colorectal cancer, renal cell carcinoma, and melanoma, with strong representation of advanced and metastatic solid tumors.
- Non-small cell lung cancer
- Urothelial carcinoma
- Pancreatic cancer
- Breast cancer
- Prostate cancer
Work in this domain also covers molecularly selected cancers and immuno-oncology approaches in difficult-to-treat malignancies.
Immune-Mediated and Inflammatory Disorders
Clinical research includes Crohn’s disease, ulcerative colitis, atopic dermatitis, hidradenitis suppurativa, and primary biliary cholangitis, alongside other immune-driven conditions such as rheumatoid arthritis, IgG4-related disease, and immune thrombocytopenia. This activity reflects a broad interest in chronic inflammatory and autoimmune disease management.
- Crohn’s disease
- Ulcerative colitis
- Atopic dermatitis
- Hidradenitis suppurativa
- Autoimmune disease
Therapeutic focus also extends to targeted immunomodulation for refractory inflammatory disorders and rare immune-mediated syndromes.
Respiratory, Cardiac, and Vascular Disease
The investigator is involved in research on heart failure, myocardial infarction, cardiomyopathy, atherosclerotic cardiovascular disease, and hypertrophic cardiomyopathy, as well as pulmonary conditions including idiopathic pulmonary fibrosis, pulmonary arterial hypertension, bronchiectasis, and cystic fibrosis. These studies span chronic cardiovascular risk and progressive respiratory disease.
- Heart failure
- Cardiomyopathy
- Idiopathic pulmonary fibrosis
- Pulmonary arterial hypertension
- Cystic fibrosis
Additional interest is seen in cardiorenal disease, vascular inflammation, and prevention of complications in high-risk cardiovascular populations.
Rare Diseases, Neurology, and Genetic Conditions
Research involvement also spans Pompe disease, transthyretin amyloidosis, Angelman syndrome, multiple sclerosis, neuromyelitis optica spectrum disorder, glioblastoma, and other rare neurological or genetic disorders. The portfolio further includes hemophilia, thalassemia, mastocytosis, and inherited metabolic conditions.
- Pompe disease
- Transthyretin amyloidosis
- Multiple sclerosis
- Angelman syndrome
- Hemophilia
Therapeutic activity includes orphan disease treatment, neurologic immunotherapy, and care pathways for genetically defined disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.